Skip to main navigation Skip to search Skip to main content

Development of palladium-based multivalent lectin-directed artificial metalloenzymes

Research output: Contribution to journal › Journal Article › peer-review

Abstract

By instilling artificial metalloenzymes (ArMs) with cancer targeting properties, these biocatalysts can be used in prodrug therapies to chemoselectively activate prodrugs within the local tumor environment. In this study, another example of a multivalent lectin-directed artificial metalloenzyme was developed using a palladium-embedded HaloTag-PduU-ACG lectin fusion protein (HtPA-Pd). By combining the targeting ArM with a proc-masked doxorubicin prodrug, this anticancer prodrug therapy was subsequently shown in assays to be biologically active against hypersialylated MDA-MB-231 breast cancer cells.

Original languageEnglish
Article number118603
Pages (from-to)118603
Number of pages1
JournalBioorganic and Medicinal Chemistry
Volume136
Early online date20 Feb 2026
DOIs
Publication statusPublished - 1 May 2026

Bibliographical note

Publisher Copyright:
Copyright © 2026 Elsevier Ltd. All rights reserved.

Keywords

  • Bioorthogonal chemistry
  • Palladium catalysis
  • Prodrug therapy
  • Artificial metalloenzyme
  • Cancer targeting

Fingerprint

Dive into the research topics of 'Development of palladium-based multivalent lectin-directed artificial metalloenzymes'. Together they form a unique fingerprint.

Cite this